SCHEMBL25249802

SCHEMBL25249802

Cc1ccc2[nH]c(-c3ccnc(N)c3)c(-c3ccccn3)c2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 2/20 0.51
TGFBR1 P36897 8/20 0.49
TGFBR2 P37173 4/20 0.49
MET P08581 1/20 0.45
TLR9 Q9NR96 3/20 0.44
TLR8 Q9NR97 3/20 0.44
TLR7 Q9NYK1 3/20 0.44
DYRK1A Q13627 2/20 0.41
ULK1 O75385 1/20 0.41
CDK7 P50613 1/20 0.41
CDK5 Q00535 1/20 0.41
PRKCE Q02156 1/20 0.41
CAMK2G Q13555 1/20 0.41
CDK5R1 Q15078 1/20 0.41
RPS6KA1 Q15418 1/20 0.41
AAK1 Q2M2I8 1/20 0.41
MAP3K19 Q56UN5 1/20 0.41
CAMKK1 Q8N5S9 1/20 0.41
CAMKK2 Q96RR4 1/20 0.41
CBFB Q13951 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25207936 0.87 TGFBR1 (0.48) RAF1TGFBR1TGFBR2METDYRK1A
SCHEMBL25201249 0.86 MET (0.49) RAF1TGFBR1TGFBR2METTLR9
SCHEMBL30365622 0.86 MET (0.49) RAF1TGFBR1TGFBR2METTLR9
SCHEMBL25217309 0.86 MET (0.49) RAF1TGFBR1TGFBR2METTLR9
SCHEMBL25210685 0.81 TGFBR1 (0.45) RAF1TGFBR1TGFBR2METTLR9
SCHEMBL25213588 0.80 TGFBR1 (0.77) RAF1TGFBR1TGFBR2BUB1KDM4E
SCHEMBL25209368 0.79 MAPK14 (0.42) RAF1TGFBR1TGFBR2METDYRK1A
SCHEMBL30365783 0.79 MAPK14 (0.42) RAF1TGFBR1TGFBR2METDYRK1A
Hydrochloric Acid SCHEMBL25236230 0.78 MAPK14 (0.41) RAF1TGFBR1TGFBR2METDYRK1A
Hydrochloric Acid SCHEMBL25242664 0.78 MAPK14 (0.41) RAF1TGFBR1TGFBR2METDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4509122-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2025-02-19 EP disclosed
EP-4188930-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF BAYER AG (DE) 2024-10-23 EP disclosed
US-20230391769-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-12-07 US disclosed
EP-4188930-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2023-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391769-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF CYP11B2, SDHA, UGT2B7 RAF1 2812/4885TGFBR1 4404/4885TGFBR2 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.